company background image
DXCM

DexCom NasdaqGS:DXCM Stock Report

Last Price

US$77.63

Market Cap

US$30.5b

7D

1.3%

1Y

-28.1%

Updated

04 Jul, 2022

Data

Company Financials +
DXCM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance2/6
Financial Health4/6
Dividends0/6

DXCM Stock Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

DexCom Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DexCom
Historical stock prices
Current Share PriceUS$77.63
52 Week HighUS$164.86
52 Week LowUS$66.89
Beta1.07
1 Month Change6.06%
3 Month Change-39.87%
1 Year Change-28.05%
3 Year Change113.24%
5 Year Change337.60%
Change since IPO2,544.97%

Recent News & Updates

Jun 24
Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Let's talk about the popular DexCom, Inc. ( NASDAQ:DXCM ). The company's shares saw a double-digit share price rise of...

Jun 03
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...

Shareholder Returns

DXCMUS Medical EquipmentUS Market
7D1.3%-0.1%-2.2%
1Y-28.1%-24.7%-21.2%

Return vs Industry: DXCM underperformed the US Medical Equipment industry which returned -24.7% over the past year.

Return vs Market: DXCM underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is DXCM's price volatile compared to industry and market?
DXCM volatility
DXCM Average Weekly Movement8.6%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.3%

Stable Share Price: DXCM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: DXCM's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19996,300Kevin Sayerhttps://www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

DexCom Fundamentals Summary

How do DexCom's earnings and revenue compare to its market cap?
DXCM fundamental statistics
Market CapUS$30.47b
Earnings (TTM)US$195.50m
Revenue (TTM)US$2.57b

155.9x

P/E Ratio

11.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DXCM income statement (TTM)
RevenueUS$2.57b
Cost of RevenueUS$837.60m
Gross ProfitUS$1.73b
Other ExpensesUS$1.54b
EarningsUS$195.50m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 28, 2022

Earnings per share (EPS)0.50
Gross Margin67.44%
Net Profit Margin7.60%
Debt/Equity Ratio89.8%

How did DXCM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is DXCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DXCM?

Other financial metrics that can be useful for relative valuation.

DXCM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.6x
Enterprise Value/EBITDA79.3x
PEG Ratio5.4x

Price to Sales Ratio vs Peers

How does DXCM's PS Ratio compare to its peers?

DXCM PS Ratio vs Peers
The above table shows the PS ratio for DXCM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.3x
IDXX IDEXX Laboratories
9.2x10.0%US$30.1b
RMD ResMed
8.9x8.6%US$31.6b
BAX Baxter International
2.4x5.0%US$33.0b
STE STERIS
4.6x7.9%US$21.1b
DXCM DexCom
11.8x16.3%US$30.5b

Price-To-Sales vs Peers: DXCM is expensive based on its Price-To-Sales Ratio (11.8x) compared to the peer average (6.3x).


Price to Earnings Ratio vs Industry

How does DXCM's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: DXCM is expensive based on its Price-To-Sales Ratio (11.8x) compared to the US Medical Equipment industry average (3.7x)


Price to Sales Ratio vs Fair Ratio

What is DXCM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DXCM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.8x
Fair PS Ratio9.5x

Price-To-Sales vs Fair Ratio: DXCM is expensive based on its Price-To-Sales Ratio (11.8x) compared to the estimated Fair Price-To-Sales Ratio (9.5x).


Share Price vs Fair Value

What is the Fair Price of DXCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DXCM ($77.63) is trading above our estimate of fair value ($72.1)

Significantly Below Fair Value: DXCM is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: DXCM is poor value based on its PEG Ratio (5.4x)


Discover undervalued companies

Future Growth

How is DexCom forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


29.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DXCM's forecast earnings growth (29.1% per year) is above the savings rate (1.9%).

Earnings vs Market: DXCM's earnings (29.1% per year) are forecast to grow faster than the US market (13.6% per year).

High Growth Earnings: DXCM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DXCM's revenue (16.3% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: DXCM's revenue (16.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DXCM's Return on Equity is forecast to be low in 3 years time (17.6%).


Discover growth companies

Past Performance

How has DexCom performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


59.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DXCM has high quality earnings.

Growing Profit Margin: DXCM's current net profit margins (7.6%) are lower than last year (26.2%).


Past Earnings Growth Analysis

Earnings Trend: DXCM has become profitable over the past 5 years, growing earnings by 59.3% per year.

Accelerating Growth: DXCM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DXCM had negative earnings growth (-63.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (12.9%).


Return on Equity

High ROE: DXCM's Return on Equity (8.9%) is considered low.


Discover strong past performing companies

Financial Health

How is DexCom's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: DXCM's short term assets ($3.7B) exceed its short term liabilities ($711.4M).

Long Term Liabilities: DXCM's short term assets ($3.7B) exceed its long term liabilities ($2.2B).


Debt to Equity History and Analysis

Debt Level: DXCM has more cash than its total debt.

Reducing Debt: DXCM's debt to equity ratio has increased from 27.9% to 89.8% over the past 5 years.

Debt Coverage: DXCM's debt is well covered by operating cash flow (24.7%).

Interest Coverage: DXCM's interest payments on its debt are not well covered by EBIT (2.8x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is DexCom current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate DXCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DXCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DXCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DXCM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DXCM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Kevin Sayer (64 yo)

11.08yrs

Tenure

US$11,985,324

Compensation

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD11.99M) is about average for companies of similar size in the US market ($USD13.34M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DXCM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: DXCM's board of directors are considered experienced (8.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DexCom, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: DexCom, Inc.
  • Ticker: DXCM
  • Exchange: NasdaqGS
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$30.470b
  • Shares outstanding: 392.50m
  • Website: https://www.dexcom.com

Number of Employees


Location

  • DexCom, Inc.
  • 6340 Sequence Drive
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/04 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.